Vicki Anastasi provides leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. She has over 25 years of experience in the medical device industry, with over 15 years specifically focused on global medical device strategic consulting.
Stephen Atkinson has a career in medical devices spanning 28 years, including various CEO and senior leadership positions. Steve spent 10 years at Johnson & Johnson and 6 years at CR Bard, and was part of the senior leadership team at Zeltiq Aesthetics noted for groundbreaking targeting of medical devices at consumers, with a successful IPO exits.
John Babitt is the EY MedTech leader for the Americas and is also the Life Sciences Leader for Financial and Accounting Transaction Advisory. John has over 20 years of experience, all in the healthcare industry, and originally joined E&Y in 1995. John’s corporate clients include but not limited to: Medtronic, Johnson & Johnson (including DePuy), Fresenius, GE Healthcare and Bayer, and significant PE clients including, Apax, Warburg Pincus, Avista Capital, Linden and Altaris.
Serge Bernasconi has more than 30 years of experience in the world of pharmaceuticals and medical devices, working in companies such as Johnson & Johnson, Schering Plough in US and Europe, and more recently Medtronic. In his capacity as President & International Regional Vice President of Medtronic France, he was elected President of APIDIM (The French Association for the Promotion of Innovation in Medical Devices), and Vice President and Treasurer of SNITEM (French Medical Technology Industry Association).
Alessio Beverina co-founded and manages a new VC firm, Panakes Partners, that finances medical innovative companies, with extremely promising products and great ambition, in Europe and Israel.
Alessio has 9 years VC experience in Sofinnova, one of the largest European VCs, grown internally from Analyst to Partner positions, with European and American exposure, focused in energy, IoT, cleantech, hardware and semiconductor sectors.
Dr. Binur is a managing partner of Orchestra and has over 29 years of venture capital experience in the United States, Europe and Israel. He is co-founder of Accelerated Technologies, Inc. and served as its Chairman of the Board since its inception. He was founding Managing Partner of Medica and while there helped raise its first two venture funds and is a pioneer in the field of interventional pulmonology.
Eamon has over 25 years MedTech experience and is founder and CEO of Neuravi Ltd. a stroke interventional company that exited to J&J in April 2017. Over the course of Neuravi he raised €41m over a number or funding transactions.
Prior to Neuravi, Eamon led international teams as both Global Director of R&D and Director of New Ventures at Abbott Vascular. He was a member of the founding team of MedNova Ltd., a company that pioneered embolic protection for carotid stenting and helped lead the company to a $100M exit to Abbott Vascular in 2005. Eamon has an engineering background and is a prolific inventor with over 220 US patents, granted or pending.
David Cassak has more than 30 years of experience in the health care industry. Cassak co-founded Windhover Information Inc., and also served as Vice President, Content, and Managing Director, Medical Devices for Elsevier Business Intelligence, a Reed Elsevier Company which included the publications In Vivo, Startup, RPM Report, Medtech Insight, The Gray Sheet and The Pink Sheet.
Chris Cleary is Vice President of Corporate Development for Medtronic. During 2014, Chris led the corporate development efforts for Medtronic’s $43B acquisition of Covidien. Since then, Medtronic has acquired over 30 businesses for more than $3 billion, and made more than 20 investments in companies and funds in excess of $170 million. Prior to 2014, Chris was CEO for Alesia Capital Services LLC, and worked at GE Capital from 1995 to 2011, leading M&A teams that closed acquisitions worth $60 billion of financial assets across more than 200 transactions.
Adelaide Cracco is the Head of Life Sciences at the European Investment Fund (EIF), institution that supports entrepreneurship and innovation across Europe, providing financing to SMEs as a cornerstone investor in venture and growth capital funds.
Michelle Cuddigan is a key member of the EMEIA Life Sciences Advisory team, with a focus on R&D Excellence, Quality Management Systems, Regulatory Compliance. Global EY solution lead for IDMP.
Louis de Lillers is a high-tech entrepreneur and has a background in corporate finance. Prior to joining CorWave, he was co-founder and CEO of PlugMed, a medtech company developing innovative devices for LVADs and hemodialysis. Being a self-trained computer programmer, Louis founded several ventures in the early 2000s and consequently joined Ernst&Young, where he embarked on missions with SMEs and high-growth companies. He subsequently became analyst at Clipperton Finance, a corporate finance boutique, focusing on mergers & acquisitions and venture capital transactions. He was then part of the information technology investment team at Sofinnova Partners.
Janke is responsible for Gilde’s European healthtech investment activities. Prior to Gilde, Janke was a Venture General Manager and head of business development at Philips’s Corporate Venturing unit. He also served as Engagement Manager at McKinsey, advising clients on growth strategies and cofounded a Nanotech company in the Silicon Valley.
Dodds joined LivaNova in January 2018 with more than 25 years of medical device experience, most recently serving as Vice President, Strategic Planning at Johnson & Johnson Medical Devices. At J&J, Dodds led the strategic planning process for the Medical Devices business and worked closely with the business development and investor relations teams. Prior to joining J&J, Dodds spent more than 20 years as a medical device equity analyst.
Chris Eso is Vice President of Corporate Development for Medtronic, specifically covering the Cardiac and Vascular Group business units, including Cardiac Rhythm and Heart Failure (CRHF), Coronary and Structure Heart (CSH), and Aortic, Peripheral Vascular and endoVenous (APV). Chris has more than 18 years of successful professional experience with the majority of his experience in a business/corporate development and strategy capacity within the pharmaceutical and medical device industries, in addition to Medtronic, including Allergan, Watson, Agilent Technologies and Peregrine Pharmaceuticals.
Mike Favet joined KCK as a Managing Director, Medical Technologies in 2016. Prior to joining KCK, he served in senior management positions for a variety of medical technology companies including Advanced Cardiac Therapeutics, Sonitus Medical, Ventus Medical, Boston Scientific and Guidant. KCK Group is a large, single family, evergreen fund that invests in multiple sectors including through a team focused on medical technology.
Anita Finnegan founded Nova Leah (and SelectEvidence) and is the Author and International Project Leader of IEC 80001-2-8 and IEC 80001-2-9. As an internationally recognized expert in Medical Device Cybersecurity she also has a strong background in software quality processes, engineering and quality engineering roles across multiple highly regulated domains.
Joseph Gatewood has primary responsibility for AdvaMed’s policy and advocacy work in the United Kingdom, Germany, other EU-15 initial member countries, and Korea. He leads our patient and trade group advocacy in the UK and Germany along with EU’s regulatory reforms relating to medical device and IVD. He also heads the Global Department’s efforts on global reimbursement, health technology assessment (HTA) and procurement issues, which encompasses challenges in China and other emerging markets.
Hanson is a Venture Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013.
Hanson is also currently a Managing Partner at the Foundry, LLC. The Foundry is the premier medical device company incubator and a preferred partner to LSV. Since its inception in 1998, The Foundry has founded and financed over a dozen medical device companies. Success stories include Ardian (acquired by Medtronic), eValve (acquired by Abbott), and Concentric (acquired by Stryker).
Claudio Giuliano is a player in the venture capital industry since year 2000. Claudio co-founded in 2007 Innogest Capital, a Venture Capital firm with about € 200 Mln under management, and a partner in the Healthcare and Cardiovascular practice at Innogest. Prior to Innogest, Claudio was Associate Director at The Carlyle Group (London), Strategy consultant at Bain & Co (Italy), and Supply Chain Manager at Hewlett-Packard (California and France).
Townsend Goddard is currently leading a commercial organization across the EMEA region delivering above market growth in five surgical business units. Additionally, he is the executive sponsor for Olympus’ business development efforts in the region. Prior to joining Olympus, he held international leadership positions at both Covidien and Stryker.
Paul Grand is MedTech Innovator’s CEO. He founded and has managed MedTech Innovator as a program within RCT Ventures for the past four years. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. He has spent the last 11 years as Managing Director for RCT Ventures, the investment arm of Research Corporation Technologies, Inc.
Laurent Grandidier joined Xeltis from medical device company Endosense, where he was vice president in charge of global commercialization and portfolio management. Grandidier previously held leadership positions at a number of brand name global medical device companies, including Teleflex Medical, Boston Scientific and Guidant.
James Greene is a serial entrepreneur and has founded and served as CEO for four medical device start-ups and currently serves as a member of the Wallace Coulter Oversight committee where he participates in the translation of innovative technologies from the Georgia Institute of Technology and Emory University, Atlanta, Georgia into successful new commercial ventures.
Annika Grosse has been with IBM since 1997. She has a background in Business and IT Consulting, becoming an Executive Partner in 2011. Three years later, Annika began her current responsibility as Consulting Leader for Watson in Europe, now the Cognitive Health Leader in Europe.
Tim Haines has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth, Tim has taken board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Proteon Therapeutics, Sientra and VirionHealth.
Jason Hannon joined Mainstay Medical as Chief Executive Officer and as a Director in October 2017. Mr. Hannon has extensive experience in the medical devices industry; he previously served as President and Chief Operating Officer of NuVasive a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions.
Gérard is a serial entrepreneur in the MedTech industry. Prior to cofounding MD Start I, he founded Technomed International, a company developing non invasive therapeutic technologies dedicated to Urology, IMMI developing neurosurgery image-guided robotic systems and SOMETEC developing non invasive hemodynamic monitoring dedicated to Intensive Care. The three companies posted successful exits by acquisition. Most recently as CEO, he turned around SpineVision, a developer and Manufacturer of Spinal Implants. Gérard Hascoët is also Chairman of EOS Imaging (France), Director of the Board of CorWave (France), Director of the Board of APD (France), Director of the Board of SafeHeal (France) and Director of the Board of Altamir (France). He is also Venture Partner for the French-based Venture Capital firm Sofinnova Partners.
Liam Kiely has over 20 years’ corporate finance and capital markets experience, having worked as an independent consultant in both Dublin and London, and held roles with Goodbody Corporate Finance and the New York office of Societe Generale (USA). He has worked closely with Irish companies at all stages of development from early stage to IPO and trade sale, and has raised several hundred million euros on international Capital Markets.
Justin Klein joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of Advanced Cardiac Therapeutics, Cartiva, ChromaCode, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS.
Piergiulio Lauriano, MBA, is a strategist and innovator that combines a passion for business and finance with his hands on technology background. At Alira Health he works between the Management Consulting and Investment Banking divisions where he advised a number of blue chip companies often at the intersection of Medtech, Biotech and Digital Health domains focusing on portfolio innovation and prioritization, business planning, organic and inorganic growth.
Paul LaViolette brings over 35 years of global medical technology management experience to SV and heads SV medical device investments. Paul built and ran medical device businesses for 29 years before joining SV Health Investors and was most recently Chief Operating Officer at Boston Scientific. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations.
Amy Len Kobe is a Director with Baxter Ventures, the corporate strategic venture arm of Baxter International. Founded in 2011, Baxter Ventures invests in innovative technologies, products and therapies that have the potential to accelerate growth for the organization as well as drive forward our mission of saving and sustaining lives. Prior to Baxter, Amy was with Healthbox, an investor and business accelerator of early-stage innovation in healthcare technology. Amy launched accelerator programs in multiple locations and raised micro venture funds, completing seed and follow on investments.
Prior to co-founding Innovation In Medtech, Stephen Levin served as Executive Editor & General Counsel at Windhover Information followed by Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry. Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations while also participating in other Senate investigations including the Whitewater inquiry.
Justin Lynch is a Partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over a 25 year experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science.
Mirren is Senior Director of New Ventures & Transactions and Medical Devices at Johnson & Johnson Innovation. He leads identification and transactions of innovative early stage medical devices, to support Johnson & Johnson across EMEA.
He joined Johnson & Johnson in 2013 leading a number of programmes leveraging innovative digital platforms to empower patients, improve clinical workflows & patient outcomes across a variety of clinical specialties. Prior to this role he was a member of the healthcare practice at The Boston Consulting Group in London, advising pharma, medtech, payers and providers on key strategic issues including business development, growth strategies and sales & marketing.
Peter Markham is a well known and accomplished executive with 25 years of management and regulatory experience in the field of GLP contract research. Prior to joining CBSET, Mr. Markham served as General Manager of the Worcester/Southbridge division of Charles River Laboratories where he had P&L responsibility for a multi-disciplinary pre-clinical business unit which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets.
Bruno Montanari is a Partner at Seroba Life Sciences. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology and medical device industries. Prior to joining the firm in 2017, Bruno was a Partner at Omnes Capital (Paris) in charge of the life sciences investments for the venture capital team.
As Vice President of Business Development and a member of the Medical Devices Group Operating Committee, Susan has responsibility for licensing, acquisitions and divestitures for the Medical Devices Group.
Susan joined Johnson & Johnson as a college recruit in the Finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within Finance and Business Development. Susan has been involved in a number of significant transactions within Medical Devices.
Carol Murphy is a Director at EY Advisory. Since coming to EY, she has developed EY’s IT Advisory offering in Ireland including IT Strategy and Architecture, IT Transformation and Technology Enablement. She also recently took on a leadership role to build and grow the company’s IT Risk Advisory offering, including cyber and data protection (GDPR), IT Governance and IT Performance, Programme Assurance and Digital Assurance. Carol has worked across a number of clients in the life sciences sector, where she led a number of IT security, risk and controls engagements. Carol has also worked with a number of clients in the health sector, such as the HSE and hospital groups, and the HPRA (formerly the Irish Medicines Board). Carol has acted as a mentor for participants as part of the NDRC digital health initiative.
Evan Norton joined Abbott in 2010, as Director of Abbott Ventures and took over primary responsibility for the organization in 2014. Prior to joining Abbott, he was a Principal at ONSET Ventures. He also held positions at Acclarent, Inc., Johnson & Johnson, Stryker Corporation, JPMorgan and PwC.
Daniel O’Mahony is a Partner at Seroba Life Sciences and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology).
Rajan Patel is a medical device executive with extensive experience in diagnostics, critical care, patient monitoring, imaging, and lab products. During his 30+ year medical device-focused career, he led numerous Research & Development and manufacturing teams, successfully launching products to aid laboratory and health care professionals and improve patient care.
Jenell Paul-Robinson, MSN, RN is Vice President, Clinical Value and Provider Relations at MedTech Innovator. She received her master’s degree in Nursing Administration from UCLA. Jenell brings over 20 years clinical nursing, strategic sourcing, and hospital organization value analysis experience to the team. She served on several national supply chain and academic medical center value analysis professional committees.
Anne Portwich, PhD, has been with LSP since 2001. She is a Partner in LSP’s Amsterdam office. Her prime focus and responsibility within LSP is to invest in unlisted securities. Over the years, she has been responsible for investments in numerous portfolio companies of LSP, such as Sapiens (acquired by Medtronic in 2014), Nexstim (IPO in 2014), and ActoGeniX (acquired by Intrexon in 2015). When the first LSP Health Economics Fund was launched in 2012, she became part of the investment team managing this fund, leading investments in companies such as ViCentra, Mint Solutions, Vivasure Medical and Neuravi (acquired by Codman Neuro in 2017).
Stan Rabinovich joined Edwards Lifesciences in 2004 when Edwards acquired Percutaneous Valve Technologies, Inc. (PVT) of which he was co-founder, Executive Vice President and COO. PVT has pioneered the development of transcatheter heart valves. Prior to PVT, Stan was Corporate Director of Business Development for Datascope Corp.
Thom Rasche has been a partner at Earlybird Venture since 2007 where he focuses on the healthcare technology sector. Mr. Rasche joined Earlybird Venture Capital GmbH & Co as a Venture Partner in 2003. Since he joined Earlybird, he has been responsible for the medical device portfolio and for making new investments in this area.
Josep Sanfeliu focuses on medtech investments and on structuring transactions. Josep serves on the board of MedLumics, Dermalumics,CVRx , Corwave, Anaconda Biomed, Babyscripts and Xeltis. Josep has over 15 years of experience in law, corporate finance and business development in connection with entrepreneurs and with intellectual property related companies.
Dan Sheehan manages the activities of Medtronic/Covidien Ventures. Dan is passionate about working with the managers of entrepreneurial companies and understands the complexity of commercializing new medical technologies with extensive background within venture capital investing and operating company management roles in the healthcare sector. Prior to Covidien, Dan was a General Partner with Affinity Capital Management, a healthcare-oriented venture capital firm in Minneapolis.
Aneta Sottil has 12 years of experience in the life sciences industry. Prior to joining EdRIP, she was a Director at Norgine Ventures, a fund backed by Norgine Pharma. Prior to Norgine Ventures, Aneta advised pharma, biotech and medtech companies within the healthcare investment banking teams of Rothschild and Bank of America. Aneta holds a Masters degree in Finance from Warsaw School of Economics and Singapore Management University.
Reinhilde Spatscheck, founder of SHS Capital, has spent eight years as management consultant with McKinsey & Co. Inc., most recently as senior engagement.
Dr. Rainer Strohmenger has over 20 investments in start-up companies. Rainer is one of Europe’s most experienced venture capitalists in Life Sciences. His 19 years of investment activity have involved financing of some of the most successful European biotech, medtech, diagnostics and healthcare IT companies.
Damien Tappy with more than two decades of Entrepreneurship and Venture Capital experience has developed a solid experience in creating, building and exiting businesses in a number of sectors including Information Technologies, Telecom and Medical Technologies. On behalf of Endeavour, Damien currently serves on the Board of CeQur and was previously board member of Symetis (acquired by Boston Scientific), Chairman of Bitplane (acquired by Andor Technology), Chairman of GeneSystems (acquired by Pall Corp) and Director of Cirpack (acquired by Thomson).
Chas Taylor has over 20 years’ experience in the medical device industry. He has been involved in successful medical device start-up companies since 1996. He co-founded embolic filter and carotid stent specialist MedNova which was acquired by Abbott in 2005. Before this he worked with CR Bard for 12 years in various sales, marketing and general management roles. During this time he was based in the USA for eight years in senior positions including Vice President for Bard Cardiovascular.
Zeev Zehavi is Vice President of Venture Investments for Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and joined in 1999. Mr. Zehavi’s background covers an extensive array of healthcare and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America.
Yu Zhang is a head of unit at the European Investment Bank (EIB) in the Equity New Products and Special Transactions department, with a focus on venture debt financing of life science companies across Europe. Since 2015, EIB has built a portfolio of over EUR 500m with more than 20 venture debt investments in the life science sector.